Primary Objective: To determine if apixaban is noninferior to warfarin (INR target range 2.0-
3.0) in the combined endpoint of stroke (ischemic or hemorrhagic or of unspecified type) and …

The direct factor Xa inhibitor apixaban (Eliquis®) has predictable pharmacodynamics and
pharmacokinetics and does not require routine anticoagulation monitoring. This article …

Atrial fibrillation is an irregular heart rhythm, and it is one of the most common cardiac
arrhythmias. It is associated with a five times increase in the risk of stroke. Anti-coagulants …

The factor Xa inhibitor apixaban is one of the novel anticoagulants to emerge as alternatives
to long‐standing standards of care that include low‐molecular‐weight heparin and warfarin …

Background Patients with atrial fibrillation who are vitamin K antagonist (VKA)-naive may
have a higher risk of thrombosis and/or bleeding than VKA-experienced patients. Methods …

Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with
vitamin K antagonists (VKAs). Vitamin K antagonist use is limited, in part, by the high …

Atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia in the
United States, and it increases the risk of stroke by about 5-fold. Stroke can result in …

Summary Background The Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at …

The objective of this review is to summarize data from the Apixaban for Reduction in Stroke
and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) and Apixaban Versus …

Background Apixaban was shown to be superior to adjusted-dose warfarin in preventing
stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional …